This demonstrates that insulin resistance is likely implicated in the early stages of MASLD/MASH, and that the loss of CEACAM1 in the two most prominent cell populations in the liver constitutes a unifying mechanism underlying hepatic fibrosis (and inflammation) in the advanced stages of the disease. This evidence concerns the gene CEACAM1 and metabolic dysfunction-associated steatotic liver disease.